Status:

COMPLETED

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Lead Sponsor:

Yale University

Collaborating Sponsors:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Obesity

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Detailed Description

A randomized, double-blind, placebo-controlled 12-week study with GLP-1 analogue (semaglutide) in men and women with obesity (BMI 30-49.9 kg/m2) in a validated laboratory model to identifying processe...

Eligibility Criteria

Inclusion

  • BMI ranging from 30-49.9 kg/m2
  • No significant medical problems, including diabetes
  • No history of HgbA1c \<6.5%
  • English speaking and able to read English and complete study evaluations
  • Able to provide informed written and verbal consent

Exclusion

  • Any significant current medical conditions, including neurological, renal, thyroid, cardiovascular, liver, endocrine or immune conditions, including diagnosis of T2DM or T1DM by American Diabetes Association (ADA) criteria
  • Meet current or past DSM-IVR criteria for alcohol dependence or any substance use disorders, including nicotine, or psychiatric disorders, including eating disorders, or use of any psychiatric medications, including anxiolytics, antidepressants, naltrexone or antabuse, anti-smoking medications
  • Current active participation in a weight loss program or weight loss of \>10% of total body weight during the prior 6 months
  • Taking any other anti-obesity medication
  • History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal

Key Trial Info

Start Date :

February 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 19 2024

Estimated Enrollment :

96 Patients enrolled

Trial Details

Trial ID

NCT04779697

Start Date

February 1 2021

End Date

November 19 2024

Last Update

February 12 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Yale Stress Center: Yale University

New Haven, Connecticut, United States, 06519